HIV-1, 2
Greater than 90.0% as determined by SDS-PAGE.
Description
HIV-1,2 recombinant- E.Coli derived recombinant 27 kDa protein contains the C- terminus of gp120 and most of gp41. The protein is conjugated to a 23 amino acids synthetic peptide derived from gp36 of HIV-2.
Product Specs
This recombinant HIV-1,2 protein, expressed in E. Coli, comprises the C-terminal region of gp120 and most of gp41 from HIV-1, conjugated to a 23 amino acid synthetic peptide from HIV-2's gp36.
The purity of the HIV-1,2 protein is greater than 90%, as assessed by SDS-polyacrylamide gel electrophoresis (SDS-PAGE).
Product Science Overview
The human immunodeficiency virus (HIV) is a complex retrovirus that has two main types: HIV-1 and HIV-2. Both types have distinct genetic and structural differences, but they share similar mechanisms of infection and replication. The envelope glycoproteins of these viruses play a crucial role in the virus’s ability to infect host cells. The HIV-1 envelope glycoprotein is composed of gp120 and gp41, while the HIV-2 envelope glycoprotein consists of gp125 and gp36 .
The HIV-1 envelope glycoprotein is a trimeric complex composed of three gp120 and three gp41 molecules. Gp120 is responsible for binding to the CD4 receptor on the surface of host cells, which is the first step in the viral entry process. After binding to CD4, gp120 undergoes a conformational change that allows it to interact with a co-receptor, usually CCR5 or CXCR4. This interaction triggers further conformational changes in gp41, which then mediates the fusion of the viral and host cell membranes, allowing the viral RNA to enter the host cell .
The HIV-2 envelope glycoprotein is similarly structured, with gp125 serving the role of gp120 in HIV-1, and gp36 serving the role of gp41. Gp125 binds to the CD4 receptor and co-receptors, facilitating the initial steps of viral entry. Gp36 then mediates the fusion of the viral and host cell membranes. One notable difference between HIV-1 and HIV-2 is that HIV-2 is generally less pathogenic and has a slower rate of disease progression .
The recombinant HIV-1 envelope conjugated to HIV-2 gp36 is a chimeric protein that combines elements of both HIV-1 and HIV-2 envelope glycoproteins. This recombinant protein is designed to leverage the immunogenic properties of both gp41 (from HIV-1) and gp36 (from HIV-2). The goal of creating such a recombinant protein is to develop more effective vaccines and therapeutic strategies that can target conserved regions of the virus, potentially offering broader protection against different HIV strains .
- Vaccine Development: The recombinant HIV-1 envelope conjugated to HIV-2 gp36 is being explored as a potential vaccine candidate. By combining conserved epitopes from both HIV-1 and HIV-2, researchers aim to elicit a robust immune response that can neutralize a wide range of HIV variants.
- Therapeutic Strategies: This recombinant protein can also be used in the development of therapeutic antibodies and other antiviral agents. By targeting conserved regions of the virus, these therapies may be more effective in preventing viral escape and resistance.
- Diagnostic Tools: The recombinant protein can be used in diagnostic assays to detect antibodies against HIV-1 and HIV-2. This can improve the accuracy of HIV testing and help in monitoring the immune response in vaccinated or infected individuals .
